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Anaplasma marginale is an important vector-borne rickettsia of ruminants in tropical and subtropical regions of 
the world. Immunization with purified outer membranes of this organism induces protection against acute anaplas-
mosis. Previous studies, with proteomic and genomic approach identified 21 proteins within the outer membrane im-
munogen in addition to previously characterized major surface protein1a-5 (MSP1a-5). Among the newly described 
proteins were VirB9, VirB10, and elongation factor-Tu (EF-Tu). VirB9, VirB10 are considered part of the type IV 
secretion system (TFSS), which mediates secretion or cell-to-cell transfer of macromolecules, proteins, or DNA-
protein complexes in Gram-negative bacteria. EF-Tu can be located in the bacterial surface, mediating bacterial 
attachment to host cells, or in the bacterial cytoplasm for protein synthesis. However, the roles of VirB9, VirB10, and 
TFSS in A. marginale have not been defined. VirB9, VirB10, and EF-Tu have not been explored as vaccine antigens. 
In this study, we demonstrate that sera of cattle infected with A. marginale, with homologous or heterologous isolates 
recognize recombinant VirB9, VirB10, and EF-Tu. IgG2 from naturally infected cattle also reacts with these proteins. 
Recognition of epitopes by total IgG and by IgG2 from infected cattle with A. marginale support the inclusion of 
these proteins in recombinant vaccines against this rickettsia.
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Anaplasmosis is an important vector-borne rickett-
sial disease of ruminant livestock in tropical and sub-
tropical regions of the world (Palmer et al. 1986), includ-
ing South America (Barros et al. 2005). The disease is 
caused by Anaplasma marginale, an ehrlichial pathogen 
of the genogroup II (Dumler et al. 2001), and is char-
acterized by fever, anemia, general weakness, pallor 
of mucous membranes, weight loss (Ajayi et al. 1978), 
abortion (Correa et al. 1978), decreased milk produc-
tion, and mortality during the acute phase of infection 
(Palmer et al. 1986).
Current methods of control of anaplasmosis include 
immunization of susceptible animals with infected 
blood from carrier cattle (premunition) or infection with 
attenuated live or less pathogenic Anaplasma centrale 
live vaccines (Kocan et al. 2003). Such immunogens are 
derived from blood of infected cattle, resulting in a high 
cost of production and risks of widespread transmission 
of unknown or newly emergent pathogens (Palmer et al. 
1999). Consequently, current research emphasizes the 
identification of the effectors of protective immunity 
and of the A. marginale epitopes targeted by these effec-
tors, with the goal of developing a standardized and safe 
vaccine (Palmer et al. 1999).
Cattle immunized with initial bodies or their outer 
membrane showed significantly less reduction of packed 
cell volumes and lower rickettsemias after challenge with 
virulent A. marginale, as compared with non-immunized 
animals (Montenegro-James et al. 1991, Tebele et al. 1991, 
Rodriguez et al. 2000). 
In the outer membrane of A. marginale, six major sur-
face proteins (MSP) were initially characterized:  MS-
P1a, MSP1b, MSP2, MSP3, MSP4, and MSP5 (Palmer 
& McGuire 1984, Barbet et al. 1987, Oberle et al. 1988, 
Tebele et al. 1991, Oberle & Barbet 1993).  However, 
none of these recombinant proteins, individually or col-
lectively, recreated the immunoprotective capacity of the 
outer membrane (Brayton et al. 2006). Therefore, com-
plete genome sequencing and proteomic analysis of the 
A. marginale membrane were undertaken (Brayton et al. 
2005, Lopez et al. 2005) to create a database that could 
be used to identify membrane proteins that might be use-
ful for vaccine development. 
Genomic analysis revealed a series of new genes of 
membrane proteins, such as the set of 14 outer membrane 
proteins genes (omps 1-14) (Brayton et al. 2005). How-
ever, proteomic analysis revealed that many proteins that 
were not annotated as membrane proteins were actually 
located or associated with A. marginale membrane, such 
as AM097 - conjugal transfer protein, AM956 - PepA 
cytosol amino peptidase, elongation factor-Tu (EF-Tu), 
VirB9, VirB10, AM197, AM854, AM127, and AM387 
(Lopez et al. 2005). 
187Antigenicity of VirB and EF-Tu of Anaplasma in natural infections • Flábio R Araújo et al.
These proteins are potential immunogens, as they 
were recognized by immunoglobulin G2 (IgG2) from 
three cattle immunized with outer membrane of A. mar-
ginale (Lopez et al. 2005). In A. marginale outer mem-
brane-vaccinated cattle, VirB9 and VirB10 also stimulate 
proliferation of memory T-lymphocytes 0 and secretion of 
Interferon-gamma (IFN-γ) (Lopez et al. 2007). Protective 
immunity against this rickettsia has been hypothesized to 
require production of IFN-γ and induction of IgG2 against 
outer membrane protein epitopes (Brown et al. 1998).
Nevertheless, these proteins may not perform the 
same way in naturally infected cattle as they did in outer 
membrane-immunized cattle, and this is a key informa-
tion to clarify the potential of VirB9 and VirB10, and 
EF-Tu as immunogens.
In this paper we describe the production of recombi-
nant VirB9, VirB10, and EF-Tu from a Brazilian isolate 
of A. marginale and determine if cattle naturally infect-
ed with Brazilian homologous and heterologous isolates 
of this pathogen produced IgG and IgG2 antibody re-
sponses against these recombinant proteins.   
MATERIALS AND METHODS
A. marginale isolate - Initial bodies were isolated 
from erythrocytes from a splenectomized calf experi-
mentally infected with a Brazilian isolate of A. marginale 
(state of Rio Grande do Norte), as described by Palmer 
and McGuire (1984). Blood was collected in vacuum 
tubes with heparin when rickettsemia reached 44%.
Genomic DNA extraction - DNA was purified from 
300 µl of infected blood by Easy DNA kit (Invitrogen, 
US). The concentration of extracted DNA and the A260/
A280 ratio were determined on a GeneQuant spectropho-
tometer (Amersham Pharmacia Biotech, USA). 
Amplification of VirB9, VirB10 and EF-Tu  - Primers 
were designed with the Oligoperfect (Invitrogen) program 
to amplify the whole ORFs of VirB9, VirB10 and EF-Tu, 
based on the Saint Maries isolate genome (NCBI acces-
sion nr: NC_004842). These primers were VirB9-F (5’ 
TGAATTTCTATAAAAACTTGCTTGC 3’), VirB9-R 
(5’ TCAAAGCACCGTATTCACTACTTC 3’), VirB10-F 
(5’-TTGAGTTTAGGGATGTCAGACG 3’), VirB10-R (5’ 
CTACCTACGCACCGCCTC 3’), EF-Tu-F (5’ ATGACA-
GAAGGGAGAAAGCC 3’), and EF-Tu-R (5’ CTACTC-
CAAAATCTCAGTTATGATACC 3’). Polymerase chain 
reaction (PCR) amplification reaction mixtures were pre-
pared in a volume of 50 µl, containing 10 mM Tris-HCl 
(pH 8.5), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM (each) de-
oxynucleoside triphosphate, 100 ηg (each) primer, 100 ηg 
of genomic DNA, and 2.5 U of Taq DNA polymerase (Cen-
biot, Brazil). Amplifications were performed in a Master-
cycler thermocycler (Eppendorf, Germany) as follows: 35 
cycles at 94°C for 1 min (denaturation), 55°C for 1 min 
(annealing), and 72°C for 1 min and 40 s (extension), and 
the last cycle was 72°C for 7 min (extension). PCR prod-
ucts were analyzed by electrophoresis in 1% agarose gel, 
stained with ethidium bromide (0.5 µg/ml).  
Cloning of VirB9, VirB10 and EF-Tu - PCR ampli-
cons were cloned in plasmid pGEM-T Easy (Promega, 
US), according to the manufacturer’s instructions. The 
recombinant plasmid was used to transform Escherichia 
coli DH5α cells. Recombinant plasmids were double di-
gested with EcoR I and inserts were subcloned in frame 
into EcoR I site of pET-47b expression plasmid (Nova-
gen, US). DH5α cells were transformed with recombi-
nant plasmids and insert orientation was checked by 
colony PCR with T7 forward primer and VirB9, VirB10 
or EF-Tu reverse primers. Selected plasmids were used 
to transform Rosetta cells (Novagen, USA). 
Production of recombinant VirB9, VirB10, and EF-
Tu - Overnight 5 ml cultures of E. coli Rosetta carry-
ing the recombinant plasmids grown in liquid selective 
Circlegrow (CG) (Bio 101, US) medium containing Ka-
namicin (25 µg/ml) and Chloranphenicol (34 µg/ml) 
were cultured in 250 ml of this medium at 37°C and 
250 rpm, until optical densities reached 0.6 (600 ηm). 
Isopropyl-β-D-thiogalactopyranoside (IPTG) was added 
at a final concentration of 1 mM. The cultures were al-
lowed to grow for 6 h. After this, E. coli cells were re-
covered by centrifugation at 10,000 g for 10 min. Pellets 
were suspended in 10 ml of 50 mM phosphate buffer and 
then frozen in liquid nitrogen. After thawing at 4ºC, the 
suspension was sonicated (Sonifier 250, Branson, USA 
- output 40) for 6 x 20 s on ice. After SDS-PAGE, re-
combinant proteins were visualized by Coomassie blue 
staining. Also, Western blots with recombinant pro-
teins and monoclonal antibody (MoAb) anti-histidine 
were performed. MoAb anti-histidine (ref. 27-4710-01, 
Amersham Pharmacia, USA) was diluted 1:6,000 in 
phosphate-buffered saline (PBS) with 0.01% of tween 
20 (PBST) and incubated for 1 h, with shaking. After 
three washes with PBST, anti-mouse IgG/peroxidase 
(ref. A-9044, Sigma, USA), diluted 1:2,000 in PBST, was 
incubated for 30 min, with shaking. The reactions were 
revealed with diaminobenzidine (DAB, Sigma)/H2O2.
Purification of recombinant proteins  - The recom-
binant proteins VirB9, VirB10, and EF-Tu were purified 
from E. coli Rosetta cell lysates by chromatography with 
agarose-Ni2+ resin (ProBond, Invitrogen). The purity of 
the recombinant proteins was assessed by SDS-PAGE.
 
Standardization of the enzyme-linked immune sorbent 
assay (ELISAs) - Optimal dilutions of antigen, sera and 
conjugate for ELISAs with VirB9, VirB10, and EF-Tu were 
determined by testing four sera negative for A. marginale 
antibodies, from cattle kept in an isolation area of Embrapa 
Beef Cattle Research Center, and four sera positive for A. 
marginale antibodies, from experimentally infected cattle. 
Status of A. marginale infection was defined by PCR for 
MSP5 gene.
ELISAs with VirB9, VirB10, and EF-TU - 96-well 
plates (ref. 3590, Costar) were adsorbed with 3.25 ηg/
well of VirB9 and VirB10, and 2.0 ηg/well of EF-Tu, di-
luted in Dulbelcco’s phosphate buffer, pH 7.2, for 12 h, at 
4ºC. Plates were blocked with PBST with 5% swim milk, 
for 1 h, at 37ºC. After five washes with PBST, positive 
and negative sera and test sera (in duplicate), diluted 
1:400 in PBST, were incubated for 60 min at 37ºC. Plates 
were then washed five times with PBST, and 100 µl/well 
of rabbit anti-bovine IgG horseradish peroxidase conju-
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gate (ref. A-7414, Sigma), diluted 1:10,000 in PBST, were 
added. Plates were incubated for 30 min at 37ºC and 
after five washes with PBST, the chromogen/substrate 
o-phenylene diamine dihydrochloride (OPD; Sigma)/ 
H2O2 was added. The reaction was stopped by addition 
of 50 µl/well of H2SO 4 (2.5 N) and results were read on 
a EL-800 ELISA reader (Bio-Tek), with a 490 ηm filter. 
Cutoffs were determined according to Frey et al. (1998).
Serum samples were from 72 Aberdeen-Angus cattle 
experimentally infected with Rio Grande do Norte ho-
mologous isolate of A. marginale; from 72 Anaplasma-
free cattle, defined by PCR for MSP5 gene (Silva et al. 
2006); from 70 cattle naturally infected with this rick-
ettsia from state of Alagoas, positive by indirect ELISA 
with MSP5 (Melo et al. 2007); and from 72 seronega-
tive cattle, all of which were analyzed by ELISAs with 
VirB9, VirB10, and EF-Tu for specific IgG. 
For titration of specific IgG2, anti-VirB9, VirB10, 
and EF-Tu IgG positive sera from 12 cattle naturally 
infected with A. marginale from state of Alagoas were 
tested by ELISA. The protocol of this test was essen-
tially the same used for total IgG, except that sera were 
diluted from 1:100 to 1:4,000; monoclonal anti-bovine 
IgG2 (MCA626, Serotec, US) was diluted 1:5,000, and 
rabbit anti-mouse IgG horseradish conjugate (A-9044, 
Sigma) was diluted 1:10,000.
Statistical analysis - Results of IgG2 titration were 
compared among groups (ELISAs with VirB9, VirB10, 
and EF-Tu) with Friedman and Tukey tests, with a degree 
of confidence of 95%.
RESULTS AND DISCUSSION
Amplification of VirB9, VirB10, and EF-Tu  - The 
amplification of VirB9, VirB10, and EF-Tu by PCR re-
sulted in fragments of 840, 1,338, and 1,118 bp, respec-
tively (Fig. 1). The size of the amplified genes match 
with the same genes in the Saint Maries isolate. Partial 
sequencing of VirB9, VirB10, and EF-Tu from differ-
ent Brazilian isolates of A. marginale suggests that they 
are conserved (unpublished observations). VirB9 and 
VirB10 were found to be highly conserved with ortholo-
gous proteins in Anaplasma phagocytophilum, Ehrlichia 
chaffeensis, and Ehrlichia canis (Lopez et al. 2007). 
VirB9 and VirB10 are components of the TFSS. 
In other Gram-negative bacteria, TFSS proteins form 
channels and facilitate secretion of molecules, and are 
required for intracellular survival (Lopez et al. 2007). 
In prokaryotes, EF-Tu can form ternary complexes with 
GTP and aminoacyl-tRNA. Aminoacyl-tRNA molecule 
that is tightly bound to EF-Tu pairs transiently with the 
codon at the A-site in the small subunit of the ribosome. 
During this step, the tRNA occupies a hybrid-binding 
site on the ribosome. The codon-anticodon pairing trig-
gers GTP hydrolysis by EF-Tu causing it to dissociate 
from the aminoacyl-tRNA, which now enters the A-site 
and can participate in chain elongation (Nilsson & Nis-
sen 2005). Nevertheless, EF-Tu can be located in the 
bacterial surface, mediating attachment to host cells 
(Granato et al. 2004).  Due to the crucial importance of 
VirBs and EF-Tu for bacteria, the genes for these three 
proteins are expected to be conserved. 
Production of recombinant EF-TU, VirB9, and 
VirB10 - Expression of VirB9, VirB10, and EF-Tu were 
confirmed by SDS-PAGE, with observed protein bands 
of 29 kDa, 55 kDa and 46 kDa, respectively (Fig. 2), 
which are approximately the predicted molecular weights 
based on the DNA sequences of the genes and coding 
fragments of the vector.
ELISAs with EF-TU, VirB9, and VirB10 - Of 72 se-
rum samples from cattle experimentally infected with 
A. marginale from Rio Grande do Norte (homologous 
isolate), defined by PCR for MSP5, 72 (100%) were also 
positive for anti-VirB9, -VirB10 and -EF-Tu antibodies 
(Table I). Of 72 sera from cattle free of infection with A. 
Fig.1: amplification of virB9, virB10, and ef-tu of Anaplasma mar-
ginale by PCR. Lanes - 1: 1 kb plus ladder (Invitrogen); 2: virb9; 3: 
virb10; 4: ef-tu.
Fig. 2: coomassie blue stained SDS-PAGE profile of Escherichia coli 
Rosetta extracts expressing VirB9, VirB10, and EF-Tu from a Brazilian 
isolate (Rio Grande do Norte) of Anaplasma marginale. Lanes - 1: 
molecular mass marker (Promega ref V8491); 2: extract of E. coli 
Rosetta, 3: Rosetta cells transformed with pET-47b/VirB9; 4: puri-
fied recombinant VirB9; 5: Rosetta cells transformed with pET-47b/
VirB10; 6: purified recombinant VirB10; 7: Rosetta cells transformed 
with pET-47b/EF-Tu; 8: purified recombinant EF-TU.
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marginale, 72 (100%) were negative for VirB10 and 71 
(98.6%) were negative for VirB9 and EF-Tu. Of 70 serum 
samples from cattle naturally infected with A. marginale 
from state of Alagoas (heterologous isolate), defined by 
ELISA with MSP5, 61 (87.1%) were also positive for 
VirB9, VirB10 and EF-Tu antibodies (Table II). All 70 
sera from anti-MSP5 antibody-negative cattle from the 
same region were also negative for VirB9, VirB10 and 
EF-Tu antibodies. These data show that VirB9, VirB10 
and EF-Tu are immunogenic in experimentally or natu-
rally infected cattle, as they elicited a specific humoral 
response that could be detected by ELISA with recom-
binant proteins. Secondly, epitopes were conserved be-
tween heterologous isolates of A. marginale (Rio Grande 
do Norte and Alagoas). Both characteristics are impor-
tant for the development of immunogens, especially in 
continental countries like Brazil.
The CD4 T cell type I response involving production 
of interferon-γ and resulting in activation of macrophages 
has been associated with immunity against intra-eryth-
rocytic pathogens (Brown et al. 1998, 2001). The Th1 re-
sponse also stimulates production of the immunoglobulin 
G2 isotype by B cells, which increases opsonization and 
consequently phagocytosis by activated macrophages 
(Brown et al. 1998). Therefore, conservation of B cell 
epitopes between and within strains is crucial for the 
clearance of Anaplasma because antibody specificity is 
important in this process.
IgG2 antibodies specific for recombinant VirB9, 
VirB10 and EF-Tu were detected in naturally infected 
cattle, with mean titers of 950, 850 and 1,250, respec-
tively (Fig. 3). IgG2 responses to EF-Tu were signifi-
cantly higher (p < 0.05) than responses to VirB10, how-
ever there were no differences between the magnitudes 
of IgG2 responses against EF-Tu and VirB9 and against 
VirB9 and VirB10 (p > 0.05). These data corroborate 
findings of Lopez et al. (2005) which demonstrated that 
VirB9, VirB10 and EF-Tu are recognized by IgG2 of A. 
marginale outer membrane-vaccinated cattle. These pro-
teins also stimulate memory T-lymphocyte proliferation 
and IFN-γ secretion Lopez et al. (2007). This is impor-
tant, as protective immune response  might require the 
interaction of humoral and cellular components.
Recognition of VirB9, VirB10 and EF-Tu by antibodies 
from cattle infected with homologous and heterologous 
isolates, and by IgG2 from cattle naturally infected with 
this rickettsia support the inclusion of these proteins in 
vaccines being developed against A. marginale. Experi-
ments of immunization with these recombinant proteins 
are been conducted at Embrapa Beef Cattle in order to as-
sess their protective potential against virulent challenge.
TABLE I
Enzyme-linked immunosorbent assay (ELISAs) with recombinant VirB9, VirB10 and elongation factor Tu (EF-TU) from Rio 
Grande do Norte isolate of Anaplasma marginale, and sera from cattle experimentally infected with this isolate and from  
A. marginale free animals
          ELISA
  VirB9 VirB10 EF-Tu
  Positive Negative Positive Negative Positive Negative 
Positive  72 0 72 0 72 0
Negative  1 71 0 72 1 71
a: defined by polymerase chain reaction (PCR) for major surface protein 5 (MSP5) gene.
Status of cattle infection with
Anaplasma marginalea
TABLE II
ELISAs with recombinant VirB9, VirB10 and EF-Tu from Rio Grande do Norte isolate of
Anaplasma marginale, and cattle sera from state of Alagoas
     ELISA
  VirB9 VirB10 EF-Tu
  Positive Negative Positive Negative Positive Negative
Positive  61 9 61 9 61 9
Negative  0 70 0 70 0 70
a: defined by ELISA with recombinant MSP5.
Status of cattle infection with
Anaplasma marginalea
Fig. 3: IgG2 titers from 12 cattle naturally infected with Anaplasma 
marginale in ELISAs with recombinant VirB9, VirB10 and Am254. 
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